With the Newly Granted IP, the Company’s IP Portfolio for the LIBERTY® System now includes 12 patents granted globally and 57 patent applications pending. The Company Continues to Scale Commercial Readiness Plans for the LIBERTY® System as it Awaits FDA Decision. HINGHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced that the United States Patent and Trademark Office (USPTO) has granted the Com ...

Core Viewpoint - The MedRobot Awards 2025 aims to recognize key players in the Chinese smart medical industry, particularly in surgical robotics, which is expected to be a highly explosive field in medical technology over the next decade [1][2]. Group 1: Award Purpose and Structure - The MedRobot Awards were established to upgrade the evaluation perspective and industry understanding from focusing solely on "devices" to a more comprehensive view that includes the entire ecosystem of surgical robotics [2]. - The awards emphasize the importance of a complete industrial chain, recognizing contributions not only in technology but also in business models, supply chain collaboration, and international expansion [3]. Group 2: Award Categories - The awards are divided into several categories, including: 1. Surgical Robot Systems 2. Industry Leadership Award for companies with deployed surgical robots [5]. 3. Technical Innovation Award for breakthroughs in system architecture and algorithms [6]. 4. Clinical Application Excellence Award for innovative clinical applications of surgical robots [7]. 5. Market Impact Award for significant achievements in market presence and clinical advancements [9]. 6. Global Expansion & Collaboration Award for successful international product deployment [11]. 7. Outstanding Supply Chain and Service Partner Awards for key supporting enterprises [13]. 8. Surgical Intelligence System Innovation Award focusing on digital and intelligent tools [15]. 9. Individual Impact Awards recognizing contributions from individuals and teams [19]. Group 3: Application and Timeline - Applications for the awards are open until July 28, 2025, with a selection phase from the end of July to August 15, 2025 [25][26]. - Award notifications will be sent out between August 21 and August 28, 2025, with the final award ceremony scheduled for September 5, 2025 [30]. Group 4: Participation and Benefits - Companies, hospitals, and research institutions can participate in the awards, with each entity allowed to submit up to three applications [28]. - Awarded entities will receive various benefits, including media exposure and opportunities for in-depth reporting and presentations at the global surgical conference [28].

Core Viewpoint - Stereotaxis will release its financial results for the second quarter of 2025 on August 7, 2025, and will host a conference call to discuss these results and corporate developments [1][2]. Company Overview - Stereotaxis is a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, focusing on the discovery, development, and delivery of robotic systems and solutions for interventional laboratories [4]. - The company's technology has been utilized to treat over 150,000 patients globally, enhancing patient care with robotic precision and safety [4]. Conference Call Details - The conference call will take place on August 7, 2025, at 4:30 p.m. ET, with dial-in numbers provided for both U.S. and international participants [2]. - A replay of the call will be available for one month following the event [3].

Core Viewpoint - The MedRobot Awards 2025 aims to recognize key players in the Chinese smart medical industry, particularly in surgical robotics, emphasizing the importance of technological advancement, clinical transformation, and industry collaboration [1][2]. Group 1: Award Purpose and Structure - The MedRobot Awards is an upgraded initiative that shifts focus from individual robotic devices to a comprehensive system approach, considering the entire surgical process from pre-operative to post-operative stages [2]. - The awards also emphasize the ecosystem surrounding medical robotics, including core components, algorithm support, and manufacturing processes, rather than just standalone innovations [2]. Group 2: Award Categories - The awards are categorized into several sections, including Surgical Robot Systems, which recognizes the entire surgical robot assembly [3]. - Specific awards include: - Surgical Robot of the Year, which is nominated from awarded companies [4]. - Industry Leadership Award for companies with deployed surgical robots in hospitals [5]. - Technical Innovation Award for breakthroughs in system architecture and algorithms [6]. - Clinical Application Excellence Award for innovative clinical applications of surgical robots [7]. - Market Impact Award for significant achievements in product registration and market expansion [9]. - Global Expansion & Collaboration Award for successful international product exports and collaborations [11]. Group 3: Supply Chain and Service Awards - The awards also cover the supply chain and service sectors, recognizing key enterprises that support surgical robots through components, algorithms, and clinical validation services [12]. - Categories include Outstanding Supply Chain Award and Outstanding Service Partner Award [13]. Group 4: Intelligent Surgery and Medical Service Robotics - The awards focus on digital and intelligent tools that enhance surgical processes, covering the entire surgical workflow [14]. - Categories include System Innovation Award for companies providing comprehensive digital capabilities [15] and various awards for medical service robotics, such as Rehabilitation Robot of the Year [18]. Group 5: Individual Impact Awards - Individual awards are designed to honor those who significantly contribute to the development of medical robotics and intelligent surgery [19]. - Categories include Surgical Robotics Clinical Leader of the Year and Entrepreneur of the Year, recognizing impactful individuals and teams [20][23]. Group 6: Application Process and Timeline - Applications for the awards are open until July 28, 2025, with a selection process occurring until August 15, 2025 [25][26]. - Award notifications will be sent out between August 21 and August 28, 2025, with the final awards ceremony scheduled for September 5, 2025 [30].

Core Viewpoint - Stereotaxis, Inc. has announced a registered direct offering to sell approximately $12.5 million of its common stock at a price of $2.00 per share, aimed at accelerating product commercialization and supporting research and development efforts [1][2]. Group 1: Offering Details - The gross proceeds from the offering are expected to be around $12.5 million, with an initial closing of approximately $8.5 million expected on or about July 18, 2025, and a second closing of $4.0 million scheduled for on or before November 25, 2025 [3]. - Lake Street Capital Markets LLC is acting as the exclusive placement agent for the offering [3]. Group 2: Use of Proceeds - Proceeds from the offering will be utilized to accelerate product commercialization, support research and development, and for other corporate purposes [2]. Group 3: Company Overview - Stereotaxis is a leader in surgical robotics for minimally invasive endovascular intervention, with a mission to develop robotic systems and solutions that enhance patient care and operational efficiency [6]. - The company's technology has been used to treat over 150,000 patients globally, indicating a significant market presence [6].

Core Insights - PROCEPT BioRobotics Corporation announced that Aquablation therapy has been assigned a Category I CPT code effective January 1, 2026, marking a significant milestone for the company and the urology community [1][3] - The new Category I CPT code 52XX1 will replace the previous Category III CPT code 0421T and is associated with a proposed national average payment of approximately $540 under the 2026 Medicare Physician Fee Schedule [2][3] - The transition to a Category I code is expected to enhance surgeon adoption and increase patient access to Aquablation therapy, which offers durable symptom relief with a low risk of sexual side effects [3] Payment Structure - The 2026 proposed payment for Aquablation therapy is set at 16.14 total RVUs, compared to 15.82 total RVUs for TURP, which translates to an average payment of approximately $529 [3] - The Proposed Physician Fee Schedule was released on July 14, 2025, and will undergo a public comment period until September 2025, with a final rule expected in November 2025 [4] Aquablation Therapy Overview - Aquablation therapy is the first and only ultrasound-guided, robotic-assisted, heat-free waterjet treatment for benign prostatic hyperplasia (BPH), providing personalized treatment planning based on real-time imaging [5][6] - The technology allows for precise removal of prostate tissue while preserving critical anatomy related to erectile and ejaculatory function, making it suitable for a wide range of patients [5][6] - BPH affects approximately 40 million men in the United States, highlighting the significant market potential for Aquablation therapy [6]

Core Insights - Microbot Medical Inc. is participating in the inaugural Endovascular Robotics session at the Society of Robotic Surgery (SRS) annual meeting, highlighting the growth and innovation in the endovascular robotics field driven by market demand [1][3] - The session will feature discussions on emerging technologies in the peripheral vascular, neurovascular, and cardiovascular spaces, with a focus on educating the medical community about the LIBERTY Endovascular Robotic System [2][3] - The SRS aims to foster education and collaboration in robotic surgery, providing opportunities for multi-centric studies and training for young professionals in the field [4] Company Overview - Microbot Medical is a pre-commercial stage medical technology company focused on redefining endovascular robotics and improving patient care globally [6] - The company has developed the world's first single-use, fully disposable endovascular robotic system, which aims to remove barriers to accessing advanced robotic systems [6] - The LIBERTY system is currently pending FDA 510(k) clearance and is not available for sale in the U.S. as the company strengthens its sales and marketing infrastructure for its launch [5]

Core Insights - Intuitive Surgical (ISRG) reported a strong first-quarter 2025 performance, with revenues increasing by 19% year-over-year to $2.25 billion and earnings per share (EPS) exceeding expectations [1][9] - The company has installed over 10,000 global systems and is witnessing growing adoption of the da Vinci 5 system, but it is facing structural challenges such as increased competition and reduced hospital capital expenditures [1][9] Financial Performance - Revenues for Q1 2025 reached $2.25 billion, marking a 19% increase compared to the previous year [1][9] - Recurring revenues constitute 85% of total revenues, indicating a stable revenue stream [2] - Gross margins are forecasted to be in the range of 65-66.5% for the full year 2025, impacted by tariffs and higher depreciation costs [2] Competitive Landscape - Intuitive Surgical is encountering rising competition, particularly from Medtronic (MDT) and Globus Medical (GMED) [4][5] - Medtronic's Hugo system is seeking FDA clearance, which could introduce significant competition in the U.S. market for minimally invasive surgery (MIS) robotics [4] - Globus Medical's ExcelsiusGPS platform is gaining traction in spinal and cranial procedures, showcasing its capabilities at GSC 2025 [5][6] Technological Edge - The company's ecosystem, which includes proven outcomes, clinical training, and an AI-enhanced surgical suite, provides a competitive advantage [3] - The da Vinci 5 system's force feedback tools are demonstrating clinical value, with studies indicating improved patient recovery and reduced surgeon error [3] Strategic Considerations - To maintain its market leadership, Intuitive Surgical must adapt to price-sensitive buyer behavior by leveraging leasing models and optimizing the utilization of installed systems [7] - The company’s long-term success will depend on navigating value-based purchasing and global reimbursement dynamics [7] Stock Performance and Valuation - ISRG shares have increased by 4.1% year-to-date, contrasting with a 9% decline in the industry [8] - The forward price-to-earnings ratio for Intuitive Surgical is 64.35, which is above the industry average but lower than its five-year median of 72.21 [11] - The Zacks Consensus Estimate for ISRG's 2025 earnings suggests a 6.8% increase from the previous year [12]

Core Insights - Microbot Medical Inc. has been granted a critical patent in China for its LIBERTY Endovascular Robotic System, marking a significant step in its global intellectual property expansion strategy [1] - The company currently holds nine patents globally and has 59 pending patent applications, which helps maintain a competitive advantage and protect the unique capabilities of the LIBERTY System [2] - Preparations for the anticipated U.S. launch of the LIBERTY System are underway, with regulatory, operational, and commercial activities accelerating [3] - The company aims to impact both developed and emerging markets, with an estimated 2 million peripheral endovascular procedures performed annually in the U.S. and approximately 2.9 million in China [4] - Microbot Medical is focused on redefining endovascular robotics and improving patient care through its innovative, single-use, fully disposable robotic system [5]

Core Insights - Microbot Medical Inc. is expanding its commercial team in anticipation of the U.S. launch of the LIBERTY Endovascular Robotic System, projected for the third quarter of 2025 [1][2] - The company is actively engaged with the FDA, expecting a 510(k) decision during the third quarter of this year, which aligns with the FDA's original review timeline [1][4] - The addition of Michael Lytle as the head of Sales Operations & Analytics is aimed at enhancing sales infrastructure and optimizing the sales cycle [2][3] Company Developments - The LIBERTY System is currently under FDA review and is not available for sale in the U.S. until clearance is granted [4] - Michael Lytle's previous experience at ZOLL Cardiac Management Solutions is expected to contribute to the company's market targeting and resource allocation [3] - The company aims to redefine endovascular robotics and improve patient care through its innovative, single-use, fully disposable robotic system [5]